Audrey Nosbaum

Audrey Nosbaum

Auto-generated profile, based on publicly available information

Audrey Nosbaum

Hospices Civils de Lyon, South of Lyon Hospital, Allergology and Clinical Immunology Department, Pierre-Bénite, France

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Cell
Verified
Journal Article
Closed access
NANiwa Ali
Niwa Ali
BZBahar Zirak
Bahar Zirak
RRRobert Sanchez Rodriguez
Robert Sanchez Rodriguez
MPMariela L. Pauli
Mariela L. Pauli
HTHong-An Truong
Hong-An Truong
MRMichael D. Rosenblum
Michael D. Rosenblum

1 November 2015 in Immunity
Verified
Journal Article
Closed access
TSTiffany C. Scharschmidt
Tiffany C. Scharschmidt
KVKimberly S. Vasquez
Kimberly S. Vasquez
HTHong-An Truong
Hong-An Truong
SGSofia V. Gearty
Sofia V. Gearty
MPMariela L. Pauli
Mariela L. Pauli
MRMichael D. Rosenblum
Michael D. Rosenblum

1 March 2016 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
ANAudrey Nosbaum
Audrey Nosbaum
NPNicolas Prevel
Nicolas Prevel
HTHong-An Truong
Hong-An Truong
PMPooja Mehta
Pooja Mehta
MEMonika Ettinger
Monika Ettinger
MRMichael D. Rosenblum
Michael D. Rosenblum
Foxp3-expressing regulatory T cells (Tregs) reside in tissues where they control inflammation and mediate tissue-specific functions. The skin of mice and humans contain a large number of Tregs; however, the mechanisms of how these cells function in skin remain largely unknown. In this article, we show that Tregs facilitate cutaneous wound healing. Highly activated Tregs accumulated in skin early after wounding, and specific ablation of these cells resulted in delayed wound re-epithelialization and kinetics of wound closure. Tregs in wounded skin attenuated IFN-γ production and proinflammatory macrophage accumulation. Upon wounding, Tregs induce expression of the epidermal growth factor receptor (EGFR). Lineage-specific deletion of EGFR in Tregs resulted in reduced Treg accumulation and activation in wounded skin, delayed wound closure, and increased proinflammatory macrophage accumulation. Taken together, our results reveal a novel role for Tregs in facilitating skin wound repair and suggest that they use the EGFR pathway to mediate these effects.

1 October 2017 in Journal of the American Academy of Dermatology
Verified
Journal Article
Open access
ESEric L. Simpson
Eric L. Simpson
MBMarjolein Bruin-Weller
Marjolein Bruin-Weller
CFCarsten Flohr
Carsten Flohr
MAMichael R. Ardern-Jones
Michael R. Ardern-Jones
SBSebastien Barbarot
Sebastien Barbarot
Amy PallerAmy Paller
Amy Paller
Although most patients with atopic dermatitis (AD) are effectively managed with topical medication, a significant minority require systemic therapy. Guidelines for decision making about advancement to systemic therapy are lacking. To guide those considering use of systemic therapy in AD and provide a framework for evaluation before making this therapeutic decision with the patient. A subgroup of the International Eczema Council determined aspects to consider before prescribing systemic therapy. Topics were assigned to expert reviewers who performed a topic-specific literature review, referred to guidelines when available, and provided interpretation and expert opinion. We recommend a systematic and holistic approach to assess patients with severe signs and symptoms of AD and impact on quality of life before systemic therapy. Steps taken before commencing systemic therapy include considering alternate or concomitant diagnoses, avoiding trigger factors, optimizing topical therapy, ensuring adequate patient/caregiver education, treating coexistent infection, assessing the impact on quality of life, and considering phototherapy. Our work is a consensus statement, not a systematic review. The decision to start systemic medication should include assessment of severity and quality of life while considering the individual's general health status, psychologic needs, and personal attitudes toward systemic therapies.

1 July 2009 in European Journal Of Dermatology
Verified
Journal Article
Closed access
PDF file
ANAudrey Nosbaum
Audrey Nosbaum
MVMarc Vocanson
Marc Vocanson
ARAurore Rozières
Aurore Rozières
Ana HenninoAna Hennino
Ana Hennino
NJNicolas Jean-Francois
Nicolas Jean-Francois
Irritant and allergic contact dermatitis are common inflammatory skin diseases induced by repeated skin contact with low molecular weight chemicals, called xenobiotics or haptens. Although both diseases may have similar clinical presentations, they can be differentiated on pathophysiological grounds. Irritant contact dermatitis (ICD) is a non-specific inflammatory dermatitis brought about by activation of the innate immune system by the pro-inflammatory properties of chemicals. Allergic contact dermatitis (ACD) corresponds to a delayed-type hypersensitivity response with a skin inflammation mediated by hapten-specific T cells. Recent progress in the pathophysiology of chemical-induced skin inflammation has shown that ICD and ACD are closely associated and that the best way to prevent ACD is to develop strategies to avoid ICD. The immunological diagnosis of ICD or ACD requires investigation of the presence (ACD) or absence (ICD) of antigen-specific T cells. The detection of T cells can be performed in the skin (collected from ACD lesions or positive patch tests) and/or in the blood, particularly by using the enzyme-linked immunospot assay (ELISPOT). This method, recently developed in ACD to metals, offers a new biological tool enabling the immunobiological diagnosis of ACD.

1 July 2019 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
SFSarah Faiz
Sarah Faiz
JGJonathan Giovannelli
Jonathan Giovannelli
CPCéline Podevin
Céline Podevin
MJMarie Jachiet
Marie Jachiet
JBJean-David Bouaziz
Jean-David Bouaziz
DSDelphine Staumont-Sallé
Delphine Staumont-Sallé